Search Results

You are looking at 81 - 90 of 177 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

David M. Dunning and Thomas A. Paivanas

Dimitrov NV . Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors

Full access

Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal

testosterone and its derivatives with some clinical efficacy. 2 However, androgen therapy fell out of favor due to concerns of aromatization to its virilizing effects, and the availability of tamoxifen and third-generation aromatase inhibitors (AIs). 3

Full access

Lauren E. Kernochan and Rochelle L. Garcia

Edited by Kerrin G. Robinson

RE Freedman DM Sherman ME Fraumeni JF Jr . Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer . J Natl Cancer Inst 2004 ; 96 : 70 – 74 . 16 Cotran RS Kumar V Collins T , eds. Robbins Pathologic Basis

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

, medroxyprogesterone acetate, megestrol acetate), and gonadotropin-releasing hormone (GnRH) analogues. Tamoxifen is not indicated for patients with uterine sarcomas, because an increased risk of developing endometrial cancer and uterine sarcoma was observed in patients

Full access

Noam VanderWalde, Reshma Jagsi, Efrat Dotan, Joel Baumgartner, Ilene S. Browner, Peggy Burhenn, Harvey Jay Cohen, Barish H. Edil, Beatrice Edwards, Martine Extermann, Apar Kishor P. Ganti, Cary Gross, Joleen Hubbard, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O'Connor, Hope S. Rugo, Randall W. Rupper, Dale Shepard, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Tanya Wildes, Mary Anne Bergman, Hema Sundar, and Arti Hurria

cancer. In a study that randomized 636 women (aged ≥70 years) treated with lumpectomy for clinical stage I estrogen receptor–positive breast cancer to either tamoxifen with whole-breast RT or tamoxifen alone, locoregional recurrence was slightly higher

Full access

Ania Syrowatka, Sue-Ling Chang, Robyn Tamblyn, Nancy E. Mayo, and Ari N. Meguerditchian

complications. Most evident, certain types of antidepressant medications indicated for the treatment of distress (eg, selective serotonin reuptake inhibitors) may interfere with tamoxifen anticancer therapy. 9 In addition, older women have a disproportionately

Full access

Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran, and Jennifer L. Lund

has been suggested that users of the hormone therapy tamoxifen are at an increased risk of venous thromboembolism compared with aromatase inhibitor users, but at a decreased risk of other cardiovascular outcomes, such as coronary heart disease. 36 – 38

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

postmenopausal women, except that tamoxifen is the preferred adjuvant treatment. 5 – 9 There are limited clinical data on the efficacy of single-agent aromatase inhibitors in men, and aromatase inhibitors may be combined with gonadotropic hormone

Full access

Rita A. Mukhtar, Jasmine M. Wong, and Laura J. Esserman

lumpectomy and tamoxifen with or without radiation. The radiation group was significantly less likely to experience local relapse at 5 years (0.6% vs 7.7%; P <.001) and axillary relapse (0.5% vs 2.5%; P =.049). However, no difference was seen in distant

Full access

Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis

. From pharmacy records, we measured nonadherence (filled prescriptions covered ≤80% of potential time on therapy), nonpersistence (continuous period >6 months when no prescription was filled), and frequency and timing of planned switches from tamoxifen